Skip to main content

Table 1 Baseline clinical data of patients with BRVO and healthy control participants in this study

From: Wide-field swept-source OCT angiography of the periarterial capillary-free zone before and after anti-VEGF therapy for branch retinal vein occlusion

Parameters BRVO eyes (n = 54) Fellow eyes (n = 54) Healthy control eyes (n = 30) P (BRVO vs. fellow) P (fellow vs. control)
Age (years, range) 60.56 ± 9.18 (45–79) 60.92 ± 5.22 (50–73) NA 0.85
Sex (male/female) 35/19 18/12 NA 0.66
Eye dominance (OD/OS) 35/19 19/35 14/16 NA 0.30
Hypertension (+/−) 31/23 13/17 NA 0.22
Mean systolic pressure (mmHg) 132.81 ± 13.67 129.68 ± 10.95 NA 0.32
Mean diastolic pressure (mmHg) 78.31 ± 8.78 79.52 ± 5.65 NA 0.53
IOP (mmHg) 14.41 ± 3.52 15.06 ± 3.00 15.84 ± 2.75 0.15 0.28
Refractive error (SE, diopter) − 0.15 ± 1.52 − 0.42 ± 1.55 − 0.24 ± 1.28 0.10 0.63
Duration of symptoms (months) 1.50 ± 1.03 NA NA NA NA
Type (ischemia/non-ischemia) 36/18 NA NA NA NA
Occlusion area (ST/IT) 38/16 NA NA NA NA
Quadrants measured (ST/IT) 16/38 16/38 9/21 NA 0.97
BCVA (ETDRS letters, Snellen equivalent) 53.56 ± 16.09 (20/90) 84.30 ± 2.49 (20/21) 84.60 ± 1.04 (20/20) < 0.01 0.56
CRT (μm) 581.70 ± 191.90 257.41 ± 26.21 260.60 ± 23.17 < 0.01 0.60
FAZ area (mm2) 0.41 ± 0.15 0.35 ± 0.09 0.32 ± 0.10 < 0.01 0.16
First-order artery      
 PaCFZ area (mm2) 0.54 ± 0.18 0.45 ± 0.15 0.42 ± 0.16 < 0.01 0.53
 Artery area (mm2) 0.49 ± 0.20 0.53 ± 0.14 0.51 ± 0.16 0.20 0.50
 P/A ratio 1.14 ± 0.22 0.84 ± 0.22 0.83 ± 0.16 < 0.01 0.78
Second-order artery      
 PaCFZ area (mm2) 0.96 ± 0.48 0.75 ± 0.25 0.73 ± 0.25 < 0.01 0.78
Artery area (mm2) 0.60 ± 0.38 0.65 ± 0.23 0.64 ± 0.24 0.25 0.88
 P/A ratio 1.83 ± 0.55 1.25 ± 0.53 1.18 ± 0.29 < 0.01 0.59
No. of IVR injections (range) 4.98 ± 2.17 (3–10) NA NA NA NA
  1. BRVO = branch retinal vein occlusion; NA = not applicable; IOP = intraocular pressure; SE = spherical equivalent; ST = superotemporal; IT = inferotemporal; BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; CRT = central retinal thickness; FAZ = foveal avascular zone; paCFZ = periarterial capillary-free zone; P/A = paCFZ area to artery area; No. = number; IVR = intravitreal ranibizumab